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Abstract
There is relatively little data on the etiology of bacterial infections in patients with sickle cell anemia (SCA) in West Africa, and no data
from countries that have implemented conjugate vaccines against both Streptococcus pneumoniae and Haemophilus inﬂuenzae
type b (Hib).
We conducted a retrospective analysis of SCA patients admitted to the Medical Research Council Unit, The Gambia, during a 5-
year period when there was high coverage of Hib and Pneumococcal conjugate vaccination. We evaluated 161 admissions of 126
patients between April 2010 and April 2015.
Pathogenic bacteria were identiﬁed in blood cultures from 11 of the 131 admissions that had cultures taken (8.4%, 95% CI
4.5–14.1%). The most frequent isolate was Salmonella Typhimurium (6/11; 54.5%), followed by Staphylococcus aureus (2/11;
18.2%) and other enteric Gram-negative pathogens (2/11; 18.2%) and there was 1 case ofH inﬂuenzae non-type b bacteremia (1/11;
9.1%). There were no episodes of bacteremia caused by S pneumoniae or Hib.
The low prevalence of S pneumoniae and Hib and the predominance of nontyphoidal Salmonella as a cause of bacteremia suggest
the need to reconsider optimal antimicrobial prophylaxis and the empirical treatment regimens for patients with SCA.
Abbreviations: CSD = Clinical Services Department, CSF = cerebrospinal ﬂuid, Hib = Haemophilus inﬂuenzae type b, MRCG =
Medical Research Council Gambia, NTS = nontyphoidal Salmonella, PCV = pneumococcal conjugate vaccine, SCA = sickle cell
anemia.
Keywords: antimicrobial prophylaxis, bacteremia, sickle cell anemia, West Africa
1. Introduction born in Africa, paradoxically there is relatively little high qualityPatients with sickle cell anemia (SCA) are at increased risk of
bacterial infections, which are leading causes of morbidity and
mortality, especially in populations that lack effective prophy-
laxis and treatment. Although >80% of people with SCA areEditor: Anna S. Levin.
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1data on infectious complications in these populations. Histori-
cally, studies from resource-rich settings have identiﬁed Strepto-
coccus pneumoniae, Haemophilus inﬂuenzae type b (Hib), and
nontyphoidal Salmonella (NTS) species to be the most common
invasive bacteria.[1–3] Studies from Africa have produced
inconsistent results, with a large study from Kenya ﬁnding
similar pathogens to those seen in western populations,[4]
whereas studies from Uganda, Nigeria, and more recently
Tanzania, showing that Staphylococcus aureus, NTS species,
and other enteric Gram-negative pathogens predominated.[5–7]
There are limited data about types of pathogens and efﬁcacy of
antimicrobial prophylaxis in West Africa and no published data
from SCA patients in The Gambia.
Penicillin prophylaxis and conjugate vaccines against S
pneumoniae and Hib have signiﬁcantly improved prognosis
and almost eliminated the additional risk of bacteremia
associated with SCA in resource-rich settings.[8–12] However,
these are not routinely implemented in much of West Africa,
despite the greatest global burden of disease.[13] The Gambia is
relatively unique in that Hib and pneumococcal conjugate
vaccines are well established as part of the Expanded Program on
Immunization.[14] The 7-valent pneumococcal conjugate vaccine
(PCV7) was introduced in 2009, followed by the 13-valent
vaccine (PCV13) in 2011[15] and the estimated proportion of
Gambian infants receiving all 3 pentavalent vaccines (containing
Hib) and PCV 13 is 89.3%.[16]
Based on the pathogen distribution found in recent studies,
some commentators have challenged the beneﬁts of penicillin
[5]
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Figure 1. Flow diagram of case identiﬁcation pathway. Vertical arrows indicate
the ﬂow of patients included in the data analysis; horizontal arrows indicate the
patients who were excluded.
Soothill et al. Medicine (2016) 95:49 Medicineprophylaxis in African populations. We aimed to review the
predominant pathogens causing invasive bacterial infections in
SCA patients admitted to the Medical Research Council Gambia
(MRCG) Unit clinical wards through retrospective analysis of
patient and laboratory records.
2. Methods
2.1. Setting and population
This study was conducted at the Clinical Services Department
(CSD) of theMRCG, located in the urban, western coastal region
where malaria transmission is relatively low.[17] The Gambia is a
small country (population 1.8 million in 2013) situated north of
the equator in West Africa. National prophylaxis guidance for
SCA recommends pyrimethamine (for malaria) and phenox-
ymethylpenicillin.
The CSD at the MRCG comprises an outpatient medical clinic
seeing around 50,000 patients a year and a 42-bed inpatient unit.
All patients with history or clinical ﬁndings suggestive of SCA are
screened using a metabisulﬁte test, followed (if positive) by
hemoglobin electrophoresis. There is no speciﬁc protocol for
management of SCA complications; however, blood cultures are
drawn from all patients with clinical features compatible with
invasive bacterial infection. Other samples from sterile sites (e.g.,
cerebrospinal ﬂuid [CSF]) are collected when clinically indicated.
A high-quality, clinical diagnostic laboratory is located at the
CSD and provides round-the-clock microbiology, hematology,
and biochemistry services. Empirical antibiotic treatment for
suspected sepsis is ampicillin and gentamicin.
2.2. Ethics
Ethical review was not required for this study since it was
undertaken as a clinical audit to establish the prevalence and causes
of invasive bacterial infections in SCApatients at theMRCGCSD.
2.3. Data collection
The admission records of all patients presenting to the CSD over a
5-year period (7th April 2010 to 7th April 2015) were reviewed.
Patients with SCA were identiﬁed from discharge diagnosis
records. We recorded whether patients were known to have SCA,
what medications were taken prior to admission, hematological
values, temperature, duration of admission, clinical diagnosis,
bacteremia or other positive sterile site culture, and sensitivities of
cultured pathogens.
We deﬁned wet season as June to November and dry season as
December to May. Severe anemia was deﬁned as hemoglobin
<50g/L. For cultural and practical reasons, all patients admitted
have axillary temperature measured, and for the purpose of this
study, a fever cut-off value of ≥37.5°C was selected, which has
been shown to increase sensitivity for predicting infection
without greatly impacting speciﬁcity.[18]
2.4. Laboratory methods
SCAwas diagnosed using hemoglobin electrophoresis. Full blood
count analysis for each patient’s sample was performed using
either the automated Medonic M Series, 3 part differential
Haematology Analyzer or the automated Cell DYN 3700, and 5
part differential Haematology Analyzer.
Blood cultures were performed using the BACTEC 9050
automated culture system. In total, 1 to 3mL blood was
inoculated into BD BACTEC PEDS PLUS/F culture for children2and 3–10mL in each aerobic and anaerobic vial for adults. Bottles
were usually placed in the incubator within 2 hours of collection.
If a delay occurred, bottles were pre-incubated at 35–37°C.
Microbiological procedureswere performed using standardmedia
if bottles gave a positive signal within 5 days, after which theywere
reported negative. Further identiﬁcation was done by cultural
morphology, Gram staining, biochemical test kits, and serological
agglutination. Staphylococcus isolates were identiﬁed by coagu-
lase, mannitol fermentation, and Catalase tests. Salmonella
Typhimurium was identiﬁed using the bioMerieux analytical
proﬁle index; API 20 E (Becton Dickinson, Sparks, MD), and
characterized by serotyping using Statens Serum Institute
Salmonella Sero-Quick kit (groups A-G) and Salmonella Sero-
Quick ID kit (speciﬁed for Typhimurium and Enteritidis). Other
enteric Gram-negatives were identiﬁed using the bioMerieux
analytical proﬁle index: API 20 E. Antibiotic susceptibility was
assessed according toCLSI interpretation guide. For the purpose of
this study, all organisms found as normal skin or oral ﬂora were
considered to be contaminants, including coagulase-negative
Staphylococci, alpha-hemolytic Streptococci (other than S pneu-
moniae), and diphtheroids.
2.5. Statistical methods
Each hospitalizationwas considered as a separate event, although
some patients were admitted more than once. Results are
reported as proportions of total number of admissions, blood
cultures or isolates, or as median values and interquartile ranges
for quantitative variables. Where appropriate, the “binom”
package in R was used to calculate Jeffrey’s 95% conﬁdence
intervals for proportions. The Mann–WhitneyU test was used to
compare the hematological parameters of patients with and
without a proven invasive bacterial infection. P value of <0.05
was used to deﬁne a signiﬁcant difference.3. Results
Data from 161 admission episodes (of 126 patients) with SCA
were included in the analysis (Fig. 1). A summary of character-
istics is shown in Table 1. Of 25 patients with >1 admission, the
median time between discharge and readmission was 87 days and
Table 1
Patients’ characteristics by the presence of invasive bacterial infection.
All subjects n=161
(number, %)
No proven invasive
bacterial infection n=146
(number, %)
Proven invasive
bacterial infection n=15
(number, %)
Age
<1 y 5 (3.1) 5 (3.4) 0 (0.0)
1–2 y 23 (14.3) 17 (11.6) 6 (40.0)
2–5 y 41 (25.5) 36 (24.7) 5 (33.3)
5–15 y 55 (34.2) 52 (35.6) 3 (20.0)
>15 y 37 (23.0) 36 (24.7) 1 (6.7)
Gender
Male 86 (53.4) 77 (52.7) 9 (60.0)
Female 75 (46.6) 69 (47.2) 6 (40.0)
Season
Wet 79 (49.1) 71 (48.6) 8 (53.3)
Dry 82 (50.9) 75 (51.4) 7 (46.7)
Diagnosis
New diagnosis 76 (47.2) 67 (45.9) 9 (60.0)
Known SCA 85 (52.8) 79 (54.1) 6 (40.0)
Medications on admission
None 105 (65.2) 95 (65.1) 10 (66.7)
Folic acid only 16 (9.9) 16 (11.0) 0 (0.0)
Pyrimethamine only 0 (0.0) 0 (0.0) 0 (0.0)
Phenoxymethylpenicillin only 1 (0.6) 1 (0.7) 0 (0.0)
Folic acid + Pyrimethamine 32 (19.9) 28 (19.2) 4 (26.7)
Folic acid + Phenoxymethylpenicillin 1 (0.6) 1 (0.7) 0 (0.0)
Pyrimethamine + Phenoxymethylpenicillin 2 (1.2) 2 (1.4) 0 (0.0)
Folic acid + Pyrimethamine + Phenoxymethylpenicillin 4 (2.5) 3 (2.1) 1 (6.7)
Length of admission
<5 d 67 (41.6) 67 (45.9) 0 (0.0)
5–9 d 65 (40.4) 62 (42.5) 3 (20.0)
≥10 d 28 (17.4) 16 (11.0) 12 (80.0)
Died 1 (0.6) 1 (0.7) 0 (0.0)
Hemoglobin
Missing data 14 (8.7) 13 (8.9) 1 (6.7)
<50 g/L 26 (16.1) 25 (17.1) 1 (6.7)
≥50 g/L 121 (75.2) 108 (74.0) 13 (86.7)
Temp on admission
Missing data 1 (0.6) 1 (0.7) 0 (0.0)
<37.5 91 (56.9) 86 (58.9) 5 (33.3)
37.5–37.9 18 (11.3) 17 (11.6) 1 (6.7)
38–38.4 20 (12.5) 18 (12.3) 2 (13.3)
≥38.5 31 (19.4) 24 (16.4) 7 (46.7)
Speciﬁc clinical diagnosis
Vaso-occlusive crisis 53 (32.9) 53 (36.3) 0 (0.0)
Pneumonia 16 (9.9) 16 (11.0) 0 (0.0)
Osteomyelitis 12 (7.5) 6 (4.1) 6 (40.0)
Sepsis unknown source 11 (6.8) 10 (6.8) 1 (6.7)
Vaso-occlusive crisis + sepsis unknown source 9 (5.6) 6 (4.1) 3 (20.0)
Dactylitis 8 (5.0) 7 (4.8) 1 (6.7)
Skin/soft tissue infection 7 (4.3) 4 (2.7) 3 (20.0)
Vaso-occlusive crisis + malaria 7 (4.3) 7 (4.8) 0 (0.0)
Anemia 6 (3.7) 6 (4.1) 0 (0.0)
Vaso-occlusive crisis + pneumonia 5 (3.1) 5 (3.4) 0 (0.0)
Malaria 4 (2.5) 4 (2.7) 0 (0.0)
Cardiac disease 4 (2.5) 4 (2.7) 0 (0.0)
Septic arthritis 2 (1.2) 2 (1.4) 0 (0.0)
Cholelithiasis 2 (1.2) 2 (1.4) 0 (0.0)
Acute chest syndrome 2 (1.2) 2 (1.4) 0 (0.0)
Aplastic crisis 2 (1.2) 2 (1.4) 0 (0.0)
Other
∗
11 (6.8) 10 (6.8) 1 (6.7)
SCA = sickle cell anemia.
∗
Meningitis and skin infection, post-infective arthralgia, acute paraparesis, submental lymphadenitis, cerebral vascular accident, gastroenteritis, nonaccidental injury, malnutrition, hepatitis, nephrotic syndrome,
avascular necrosis.
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Table 2
Comparison of patients’ hematological values on admission by the presenceof invasive bacterial infection (using theMann–WhitneyU test
no statistically signiﬁcant difference for any parameters).
All subjects No proven invasive bacterial infection Proven invasive bacteria infection P
Laboratory values
Hemoglobin, g/L, median, IQR, n 73 (57–87, 147) 72 (53–86, 133) 82 (68–97, 14) 0.07
Mean cell volume, ﬂ, median, IQR, n 79.6 (74.1–87.2, 126) 80.7 (74.2–88.8, 113) 75.8 (68.0–81.7, 13) 0.09
White cell count, 109/L, median, IQR, n 21.7 (16.7–28.3, 145) 21.8 (16.7–27.9, 132) 20.9 (17.5–33.8, 13) 0.54
Neutrophils, 109/L, median, IQR, n 13.2 (8.5–17.5, 142) 12.8 (8.4–17.4, 130) 14.6 (12.1–18.8, 12) 0.28
Lymphocytes, 109/L, median, IQR, n 6.2 (3.7–9.0, 135) 6.4 (3.7–8.8, 122) 5.0 (3.8–13.8, 13) 0.66
Platelets, 103/mL, median, IQR, n 318 (216–451, 137) 322 (223–442, 124) 278 (166–506, 13) 0.60
IQR = interquartile range.
Soothill et al. Medicine (2016) 95:49 Medicinethe minimum interval was 1 day. Five patients were readmitted
within 1 week of discharge; no culture positive patients were
recounted for the same bacterial infection. One patient had 2
admissions with positive blood cultures 1 month apart, S aureus
was cultured on their ﬁrst admission andH inﬂuenzae non-type b
on their second; they had a negative HIV test. The median length
of admission was 5 days, and there was 1 death of a patient
diagnosed with an aplastic crisis with negative blood cultures.
The median age of patients was 5 years (interquartile range
[IQR]: 2–13 years). Just under half of patients had a new
diagnosis of SCA made on admission (median age 4 years [IQR:
2–8 years]). There was no statistically signiﬁcant difference in the
hematological parameters of patients with and without a proven
invasive bacterial infection (Table 2).
Of the 161 admission episodes, 131 (81%) had blood cultures
taken, and 16 (12.2%, 95%CI 7.4–18.6%) of these were positive.
Five blood cultures (3.8%, 95% CI 1.5–8.2%) grew suspected
contaminants and 11 (8.4%, 95% CI 4.5–14.1%) yielded
pathogenic organisms. The most frequent pathogenic isolates were
NTS (6/11; 54.5%), other enteric Gram-negatives (2/11; 18.2%),
and S aureus (2/11; 18.2%). No episodes of S pneumoniae or Hib
bacteremiawere identiﬁed (0/131, 0%, 95%CI0–1.5%), but there
was 1 case ofH inﬂuenzae nontype b. 64% (7/11) of positive blood
cultures occurred in children aged under 5. Cultures from other
sterile sites (CSF and pus aspirates) were also analyzed, revealing 4
additional positive cultures (Fig. 2). One childwith a new diagnosis
of SCA, unknown immunization status, and not taking penicillin
prophylaxis, had S pneumoniae isolated from CSF.
4. Discussion
SCA is estimated to be one of the biggest causes of premature
death in West Africa, mainly attributed to infections.[19] The0 2 4
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4prevalence of SCA in The Gambia is unknown, and the lack of
prevalence data and the failure of children to be routinely
screened either at birth or on hospital admission means that it is
likely to be signiﬁcantly underestimated. Four small cross-
sectional surveys completed in rural Gambia estimated the
percentage of newborns with SCA to be between 0.8% and 1.2%,
with a high excess mortality in early childhood.[20,21]
Knowledge of the most common pathogens infecting patients
with SCA could be used to improve antimicrobial prophylaxis
and empirical treatment of infections. Variations in the
prevalence of S pneumoniae and Hib in studies of bacteremia
in SCA patients in Africa have been the cause of much debate.[22]
In this study, we found no cases of S pneumoniae or Hib
bacteremia. One case of S pneumoniae was identiﬁed from CSF
culture, and there was 1 case of H inﬂuenzae non-type b
bacteremia. S pneumoniae and Hib infections are more common
among younger SCA patients, and it has been suggested that
studies of known SCA patients in sub-Saharan Africa are missing
infections occurring in younger children due to late diagnosis of
SCA.[4] Although there are regional screening programs for SCA
in sub-Saharan Africa,[23] their coverage is minimal and diagnosis
is usually made when a complication occurs. The median age in
our study was 5 years, whereas that of children diagnosed on
presentation (just under half of subjects) was 4 years, so it is
possible that the low rates of S pneumoniae and Hib in this study
are a reﬂection of this older age range and survivorship bias.
The Gambia has a well-established vaccination program,
ahead of most other countries in sub-Saharan Africa.[14–16]
Therefore, it is highly likely that the prevalence of S pneumoniae
and Hib infections is lower than other countries. A study
conducted at MRCG before introduction of the PCV
(2003–2005) found that S pneumoniae accounted for 45.2%
of community acquired bacteremia in children, followed by6 8 10
ositive cultures  
Blood
Pus aspirate
Cerebrospinal luid
d from sterile site culture.
[24] [2] Wong WY, Powars DR, Chan L, et al. Polysaccharide encapsulated
Soothill et al. Medicine (2016) 95:49 www.md-journal.comS aureus (18.3%),E coli (9.7%), andNTS (8.6%). In contrast,
a review of causes of bacteremia in the same unit after the
establishment of these vaccination programs (2010–2014)
showed a decline in S pneumoniae to just 15.1% with S aureus
the predominant pathogen accounting for 24% of isolates (S.
Anderson, unpublished data). This trend is mirrored by recent
data from elsewhere in The Gambia.[25]
It is unlikely that the low yield of S pneumoniae observed in this
cohort of patients is due to inadequate culture facilities. In contrast
to many other low-resource settings, the MRCG has excellent
clinical facilities and a co-located diagnostic microbiology
laboratory. However, because this was a retrospective study it
was not possible to determine time from blood collection to
incubation, or the volume of blood collected for culture—both
known to impact on culture yield and likelihood of contami-
nants.[26] Nonetheless, the rate of blood culture contamination
(3.8%of blood cultures taken and 31%of positive blood cultures)
is lower than other studies in sub-Sahara Africa,[7,27] and suggests
poor technique is unlikely to have greatly inﬂuenced our results.
The retrospective nature of the study means we did not have
some information that could be important for interpreting our
results (immunization status; clinical justiﬁcation for taking
blood cultures; the decision making process used to assign a ﬁnal
diagnosis; or the serotype of the pneumococcal meningitis
isolate). We also do not have denominator or pre-vaccination
data. We do not know for certain about prior antimicrobial
treatment, which may have resulted in negative culture results.
However, only 5% of patients were documented as taking
phenoxymethylpenicillin prophylaxis on admission, suggesting
this effect may be small. Rates of bacteremia may also have been
underestimated because blood cultures were not performed on all
patients. However, our results are consistent with a recent study
in Tanzania, where similar rates of bacteremia (4.8% of
admissions) and distribution of pathogens (S aureus 28%,
NTS 21%, S pneumoniae 7%) were identiﬁed.[7] Records were
unavailable for nearly one-third of potentially eligible cases, and
we do not know what affect this missing data had on our results.
Despite the limitations of this study, it is remarkable that there
were no cases of S pneumoniae or Hib bacteremia. The
predominance of NTS species and other enteric Gram-negatives
suggests a need to re-evaluate optimal antimicrobial prophylaxis
and empirical treatment in this population.[28] Despite its success
in resource-rich settings, penicillin prophylaxis may not be
optimal for PCV and Hib-vaccinated patients with SCA in The
Gambia. However, it is unclear whether possible alternatives
such as co-trimoxazole or azithromycin would be safe or cost-
effective. For SCA patients with suspected sepsis, empirical
treatment must be effective against both NTS and S aureus, and
account for local resistance patterns. As other countries in sub-
Saharan Africa adopt PCV, they may see a changing spectrum of
pathogens in SCA patients. We suggest that further research,
including clinical trials, are needed to determine locally
appropriate treatment and prophylaxis regimens for SCA.
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